Exagen, Maker of AVISE Testing, Announces First Blood Test for Anti-CarP, a Breakthrough Bio-marker for Rheumatoid Arthritis

San Diego, CA and Albuquerque, NM, Sept. 11, 2018 – — Exagen Diagnostics, the leader in specialty rheumatology testing, announced today availability of the first validated blood test to detect autoantibodies against carbamylated proteins (anti-CarP). Studies show that this novel test can add valuable information in the management of Rheumatoid Arthritis (RA), a condition affecting over 1.3 million Americans.1Elevated levels of anti-CarP antibodies are suggestive of a more severe form of RA, more than doubling the chance for joint erosions within 3 years of a diagnosis compared to those without elevated levels. In a retrospective study, positivity for anti-CarP has also been associated with the use of more aggressive forms of therapy, such as biologic agents, to help maintain control of the disease.2Rheumatoid arthritis symptoms can progress rapidly and with little advance warning, leading to permanent and debilitating joint damage, so it is crucial that physicians stay ahead of the disease.3 “Having an advanced test like anti-CarP may offer physicians additional insights to better manage their rheumatoid arthritis patients for improved healthcare outcomes” said Dr. Arthur Weinstein, Chief Medical Officer at Exagen Diagnostics. “There are a number of clinical scenarios where this test can add significant value, for example; when patients are feeling fine and elect to forego proactive therapy recommended by their provider, or when other lab tests such as anti-CCP or anti-RF are negative.”References:Shi J, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthri­tis and predict joint damage. Proceedings of the National Academy of Sciences, 2012;108(42):17372-17377.Truchetet ME, et al. Association of the presence of anti–carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome. Arthritis Rheumatology, 2017; 69(12): 2292-2302.Verheul K, et al. The combination of three autoantibodies, ACPA, RF and anti-CarP antibodies is highly specific for rheumatoid arthritis: implications for very early detection of individuals at risk to develop rheumatoid arthritis. Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40562. [Epub ahead of print]About Lupus and Rheumatoid Arthritis
Lupus and rheumatoid arthritis are autoimmune diseases in which the body attacks its own, healthy tissues and organs. Patients suffer joint pain along with increased risk for other life-threatening conditions. Systemic Lupus Erythematosus (SLE), a more severe form of lupus brings with it a host of unwanted symptoms including unexplained fevers, hair loss, fatigue, and skin rashes. Each year millions of Americans seek out a differential diagnosis for symptoms consistent with RA and SLE. Women are more likely to suffer from these conditions than men, and there’s no definitive cause, though researchers suspect genes as well as environmental factors may play a role.
AttachmentAVISE_Woman_Rheumatoid_ArthritisBrian McEvilly
Exagen Diagnostics, Inc.
858-736-5517
bmcevilly@exagen.com

Leave a Reply

Your email address will not be published. Required fields are marked *